TrialEfficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Trial details
- Registry ID
- NCT04511130
- Phase
- Phase 2
MRKR
Marker Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130 | MRKR | Phase 2 | Terminated | 2024-03-01Actual |
Latest recorded trial changes
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
NCT04511130 · Marker Therapeutics, Inc.
Actual enrollment increased by 45 participants
− Before
47 participants (actual)
+ After
92 participants (actual)
Recruitment status changed
− Before
Completed
+ After
Terminated